IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia

Robert Kyle, Joanne Benson, Dirk Larson, Terry M Therneau, Angela Dispenzieri, L. Joseph Melton, S Vincent Rajkumar

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Immunoglobulin M monoclonal gammopathy of undetermined significance (IgM-MUS) was diagnosed in 213 Mayo Clinic patients who were residents of 11 counties in southeastern Minnesota from 1960 to 1994. During long-term follow-up, 29 (14%) developed non-Hodgkin lymphoma (n = 17), Waldenström's macroglobulinemia (WM; n = 6), chronic lymphocytic leukemia (n = 3), and AL amyloidosis (n = 3) with relative risks of 15-, 262-, 6-, and 16-fold, respectively. The cumulative probability of progression to one of these disorders was 10% at 5 years, 18% at 10 years, and 24% at 15 years, approximately 1.5% per year. Smoldering WM was identified in 48 patients at Mayo Clinic from 1974 to 1995. During follow-up, 33 of the 48 patients progressed to symptomatic WM. The median time to progression was 4.6 years. The risk of progression to WM was 6% at 1 year, 39% at 3 years, and 55% at 5 years.

Original languageEnglish (US)
Pages (from-to)17-18
Number of pages2
JournalClinical Lymphoma and Myeloma
Volume9
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Waldenstrom Macroglobulinemia
Immunoglobulin M
Amyloidosis
B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma

Keywords

  • Immunoglobulin
  • Light chain
  • Serum M protein
  • Waldenström

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia. / Kyle, Robert; Benson, Joanne; Larson, Dirk; Therneau, Terry M; Dispenzieri, Angela; Melton, L. Joseph; Rajkumar, S Vincent.

In: Clinical Lymphoma and Myeloma, Vol. 9, No. 1, 2009, p. 17-18.

Research output: Contribution to journalArticle

@article{7b897dc6eceb4cd7ac2123028c89b0b0,
title = "IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstr{\"o}m's macroglobulinemia",
abstract = "Immunoglobulin M monoclonal gammopathy of undetermined significance (IgM-MUS) was diagnosed in 213 Mayo Clinic patients who were residents of 11 counties in southeastern Minnesota from 1960 to 1994. During long-term follow-up, 29 (14{\%}) developed non-Hodgkin lymphoma (n = 17), Waldenstr{\"o}m's macroglobulinemia (WM; n = 6), chronic lymphocytic leukemia (n = 3), and AL amyloidosis (n = 3) with relative risks of 15-, 262-, 6-, and 16-fold, respectively. The cumulative probability of progression to one of these disorders was 10{\%} at 5 years, 18{\%} at 10 years, and 24{\%} at 15 years, approximately 1.5{\%} per year. Smoldering WM was identified in 48 patients at Mayo Clinic from 1974 to 1995. During follow-up, 33 of the 48 patients progressed to symptomatic WM. The median time to progression was 4.6 years. The risk of progression to WM was 6{\%} at 1 year, 39{\%} at 3 years, and 55{\%} at 5 years.",
keywords = "Immunoglobulin, Light chain, Serum M protein, Waldenstr{\"o}m",
author = "Robert Kyle and Joanne Benson and Dirk Larson and Therneau, {Terry M} and Angela Dispenzieri and Melton, {L. Joseph} and Rajkumar, {S Vincent}",
year = "2009",
doi = "10.3816/CLM.2009.n.002",
language = "English (US)",
volume = "9",
pages = "17--18",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "1",

}

TY - JOUR

T1 - IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia

AU - Kyle, Robert

AU - Benson, Joanne

AU - Larson, Dirk

AU - Therneau, Terry M

AU - Dispenzieri, Angela

AU - Melton, L. Joseph

AU - Rajkumar, S Vincent

PY - 2009

Y1 - 2009

N2 - Immunoglobulin M monoclonal gammopathy of undetermined significance (IgM-MUS) was diagnosed in 213 Mayo Clinic patients who were residents of 11 counties in southeastern Minnesota from 1960 to 1994. During long-term follow-up, 29 (14%) developed non-Hodgkin lymphoma (n = 17), Waldenström's macroglobulinemia (WM; n = 6), chronic lymphocytic leukemia (n = 3), and AL amyloidosis (n = 3) with relative risks of 15-, 262-, 6-, and 16-fold, respectively. The cumulative probability of progression to one of these disorders was 10% at 5 years, 18% at 10 years, and 24% at 15 years, approximately 1.5% per year. Smoldering WM was identified in 48 patients at Mayo Clinic from 1974 to 1995. During follow-up, 33 of the 48 patients progressed to symptomatic WM. The median time to progression was 4.6 years. The risk of progression to WM was 6% at 1 year, 39% at 3 years, and 55% at 5 years.

AB - Immunoglobulin M monoclonal gammopathy of undetermined significance (IgM-MUS) was diagnosed in 213 Mayo Clinic patients who were residents of 11 counties in southeastern Minnesota from 1960 to 1994. During long-term follow-up, 29 (14%) developed non-Hodgkin lymphoma (n = 17), Waldenström's macroglobulinemia (WM; n = 6), chronic lymphocytic leukemia (n = 3), and AL amyloidosis (n = 3) with relative risks of 15-, 262-, 6-, and 16-fold, respectively. The cumulative probability of progression to one of these disorders was 10% at 5 years, 18% at 10 years, and 24% at 15 years, approximately 1.5% per year. Smoldering WM was identified in 48 patients at Mayo Clinic from 1974 to 1995. During follow-up, 33 of the 48 patients progressed to symptomatic WM. The median time to progression was 4.6 years. The risk of progression to WM was 6% at 1 year, 39% at 3 years, and 55% at 5 years.

KW - Immunoglobulin

KW - Light chain

KW - Serum M protein

KW - Waldenström

UR - http://www.scopus.com/inward/record.url?scp=67649556699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649556699&partnerID=8YFLogxK

U2 - 10.3816/CLM.2009.n.002

DO - 10.3816/CLM.2009.n.002

M3 - Article

C2 - 19362962

AN - SCOPUS:67649556699

VL - 9

SP - 17

EP - 18

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 1

ER -